Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16796544 | 1.00 | MAPT (0.56) | MAPTALDH1A1LMNASMN1; SMN2USP2 | |
| SCHEMBL1681464 | 1.00 | MAPT (0.56) | MAPTALDH1A1LMNASMN1; SMN2USP2 | |
| SCHEMBL1994473 | 0.93 | ALDH1A1 (0.54) | MAPTALDH1A1LMNASMN1; SMN2PDE4B | |
| SCHEMBL1994474 | 0.93 | ALDH1A1 (0.54) | MAPTALDH1A1LMNASMN1; SMN2PDE4B | |
| SCHEMBL2296382 | 0.87 | KMT2A (0.44) | MAPTALDH1A1LMNASMN1; SMN2AKR1C3 | |
| SCHEMBL2294411 | 0.87 | KMT2A (0.44) | MAPTALDH1A1LMNASMN1; SMN2AKR1C3 | |
| SCHEMBL2292562 | 0.85 | SMN1; SMN2 (0.55) | MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2295706 | 0.85 | SMN1; SMN2 (0.55) | MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL323889 | 0.84 | USP2 (0.46) | MAPTSMN1; SMN2USP2PDE4BRECQL | |
| SCHEMBL497161 | 0.84 | USP2 (0.46) | MAPTSMN1; SMN2USP2PDE4BRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4430032-A1 | CATALYTIC HYDROGENATION OF AROMATIC NITRO COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-20240294458-A1 | CATALYTIC HYDROGENATION OF AROMATIC NITRO COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-09-05 | — | — | US | disclosed |
| CN-118251382-A | Catalytic hydrogenation of aromatic nitro compounds | 豪夫迈·罗氏有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2023079128-A1 | CATALYTIC HYDROGENATION OF AROMATIC NITRO COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023079128-A1 | CATALYTIC HYDROGENATION OF AROMATIC NITRO COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-05-11 | — | — | WO | disclosed |
| CN-105793430-B | Process for the preparation of chiral 2-arylmorpholines | 豪夫迈·罗氏有限公司 | 2020-03-03 | — | — | CN | disclosed |
| US-10337039-B2 | Process for the preparation of chiral 2-aryl morpholines | HOFFMANN-LA ROCHE INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10337039-B2 | Process for the preparation of chiral 2-aryl morpholines | HOFFMANN-LA ROCHE INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3080284-B1 | PROCESS FOR THE PREPARATION OF A CHIRAL 2-(4-AMINOPHENYL)MORPHOLINE | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-3080284-B1 | PROCESS FOR THE PREPARATION OF A CHIRAL 2-(4-AMINOPHENYL)MORPHOLINE | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-3080284-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | F. Hoffmann-La Roche AG (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-20160289718-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | HOFFMANN-LA ROCHE INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289718-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | HOFFMANN-LA ROCHE INC. (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289718-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | HOFFMANN-LA ROCHE INC. (US) | 2016-10-06 | — | — | US | disclosed |
| WO-2015086495-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10337039-B2 | Process for the preparation of chiral 2-aryl morpholines | TAAR1, TAAR5, TACR2 | MAPT 1295/4885ALDH1A1 400/4885LMNA 3535/4885 |
| US-20160289718-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | TAAR1, TAAR5, TACR2 | MAPT 1295/4885ALDH1A1 400/4885LMNA 3535/4885 |
| US-20240294458-A1 | CATALYTIC HYDROGENATION OF AROMATIC NITRO COMPOUNDS | NOS2, NOS1, NOS3 | MAPT 1989/4885ALDH1A1 1088/4885LMNA 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.